Skip to main content
2026 CRT Conference Main banner

Paul M. Ridker, MD

Director, Center for Cardiovascular Disease Prevention
Brigham and Womens Hospital
Brookline, Massachusetts, United States

Dr. Paul M Ridker, MD, MPH serves as the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention at the Brigham and Women’s Hospital in Boston Massachusetts USA.
Over a 30-year period, Dr. Ridker and his collaborators provided the first proof-of-principle for the inflammation hypothesis of atherothrombosis in humans; the first demonstration that statin therapy is both lipid-lowering and anti-inflammatory; the first FDA-approved diagnostic test for vascular inflammation (hsCRP); the first proven anti-inflammatory treatment for heart disease (canakinumab); and brought into clinical practice worldwide the concept of “residual inflammatory risk”. On multiple occasions Dr. Ridker’s work has altered clinical guidelines for the diagnosis, treatment, and prevention of atherosclerotic disease –

Disclosure(s): Kowa, Novartis, Amarin, Pfizer, Esperion, NovoNordisk, NHLBI, NCI: Grant/Research Support (Ongoing); Novartis, Agepha, Ardelyx, Arrowhead, AstraZeneca, CSL Behring, Janssen, Vivi Biopharm, Glaso Smith Kline, SOCAR, Novo Nordisk, Eli Lilly, new Amsterdam, Boehringer-Ingelheim, Cytokinetics, Nodthera, Tourmaline Bio, Cardio therapeutics: Consulting Fees (e.g., advisory boards) (Ongoing); Uppton, Bitteroot, Bio, Angiowave and receives compensation for service from Leducq Foundation, Paris FR: Minority shareholder equity positions (Ongoing)

Presentation(s):

Email Paul